Almost 6 out of 10 people with paroxysmal nocturnal hemoglobinuria (PNH) living in the U.S. may be being given a higher initial loading dose of Ultomiris (ravulizumab) than is recommended on the medication’s label, a database study into its clinical use reports. Researchers also observed that maintenance doses,…
Danicopan, an experimental oral medication, continued to help control anemia when taken for up to 48 weeks by adults with paroxysmal nocturnal hemoglobinuria (PNH) who experience a breakdown of red blood cells outside of blood vessels — called extravascular hemolysis — despite being on a C5 inhibitor. That’s according…
This year, PNH News brought up-to-date coverage of the latest scientific and clinical research developments in paroxysmal nocturnal hemoglobinuria (PNH). Here are the 10 most-read news stories of 2023, along with a brief description of what made them interesting to our readers. We look forward to continuing to…
Taking Novartis’ Fabhalta (iptacopan) as a monotherapy — meaning as a sole treatment — twice daily for almost one year continued to sustain hemoglobin at near-normal levels, generally without the need for blood transfusions, in adults with paroxysmal nocturnal hemoglobinuria (PNH). These new data come from an open-label…
An enzyme called lactate dehydrogenase (LDH), which is a marker of red blood cell breakdown, may be used as a proxy measure for fatigue and quality of life in people with paroxysmal nocturnal hemoglobinuria (PNH) who are being treated with Ultomiris (ravulizumab) or Soliris (eculizumab). That’s according…
People with paroxysmal nocturnal hemoglobinuria (PNH) who had a prior blood clot-related event are more likely to have such events again, regardless of whether they recently used blood thinners, a real-life registry study found. Other factors that appeared to increase their likelihood in PNH patients not on Soliris…
Unusual colon lesions caused by ischemic colitis led to the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) in an 82-year-old woman in Japan, but appropriate treatment eased her symptoms. According to the authors, her case highlights the importance of considering underlying diseases when unusual features are observed in a person…
Iptacopan, an experimental oral medication being developed by Novartis, increased hemoglobin to near-normal levels in people with paroxysmal nocturnal hemoglobinuria (PNH) — without the need for blood transfusions — according to data from two global Phase 3 clinical trials. The trials, APPLY-PNH (NCT04558918) and APPOINT-PNH (NCT04820530),…
An experimental therapy being developed by Omeros can nearly double the level of hemoglobin safely after three doses in severely anemic people with paroxysmal nocturnal hemoglobinuria (PNH). That’s according to interim data from an ongoing Phase 1b clinical trial that’s evaluating the effect of once-monthly subcutaneous (under-the-skin) injections…
Get regular updates delivered to your inbox.
